Active Funds Can’t Beat the S&P 500? One Fund Proves It
A newly launched active ETF has delivered stronger net returns than the S&P 500 after costs over the latest 12-month ...
Identify the Aristocrats ETF with the lowest fee and understand how that impacts long-term returns, including potential trade-offs.
20,652 articlesA newly launched active ETF has delivered stronger net returns than the S&P 500 after costs over the latest 12-month ...
Silver prices have surged, lifting miners' profits and spurring a new wave of income-focused ETFs. Three TSX-listed f...
Five years after investing in KWEB, the math reveals a hard lesson about concentration, fee drag, and the complexity ...
Two popular healthcare ETFs—IHE and IBB—offer very different routes to exposure: established pharma vs biotech innova...
July began with AI-driven headlines shifting attention from headlines to execution. This guide breaks down how stock ...
Choosing the right pharmaceutical ETF can feel like balancing income with growth. This guide compares VanEck's PPH an...
Healthcare investing offers breadth and specialty. This guide explains FHLC and BBH, how they differ, and how to deci...
Two popular fixed-income ETFs, LQD and TLT, offer very different paths to income and risk. This guide explains why LQ...
Two Vanguard growth-focused funds sit on opposite ends of the market cap spectrum. This guide weighs small-cap opport...
Stocks with dividends are drawing buyers as growth slows. HDV and SPYD command big flows, yet risk signals suggest on...
Two popular real estate ETFs offer distinct paths: XLRE provides a low-cost U.S. core, while RWO adds global reach. L...
In markets, hacks chase quick bets while artists build sustainable growth. This guide shows how to blend both mindset...